Regional fluid-attenuated inversion recovery (FLAIR) at 7 Tesla correlates with amyloid beta in hippocampus and brainstem of cognitively normal elderly subjects

Frontiers in Aging Neuroscience

Volumn 6, Issue SEP, 2014, Pages

  Schreiner, Simon J ^a   Liu, Xinyang ^b   Gietl, Anton F ^a   Wyss, Michael ^a   Steininger, Stefanie C ^a   Gruber, Esmeralda ^a   Treyer, Valerie ^a   Meier, Irene B ^a,c   Ka¨lin, Andrea M ^a   Leh, Sandra E ^a   Buck, Alfred ^a   Nitsch, Roger M ^a   Pruessmann, Klaas P ^a   Hock, Christoph ^a   Unschuld, Paul G ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c Department of Information Technology and Electrical Engineering Institute for Biomedical Engineering University of Zu¨rich and ETH Zu¨rich ^*  (United States)

Author keywords

7 Tesla; Aging; Amyloid beta; FLAIR; MRI; PiB PET

Indexed keywords

AMYLOID BETA PROTEIN; CARBON 11; PITTSBURGH COMPOUND B;

AGED; AGING; ARTICLE; BASAL GANGLION; BRAIN REGION; BRAIN STEM; COGNITIVE DEFECT; CORRELATION COEFFICIENT; FEMALE; FLUID ATTENUATED INVERSION RECOVERY; GERIATRIC PATIENT; HIPPOCAMPUS; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY;

EID: 84907170384     PISSN: None     EISSN: 16634365     Source Type: Journal    
DOI: 10.3389/fnagi.2014.00240     Document Type: Article

References (73)

1. Adams, J. G., and Melhem, E. R. (1999). Clinical usefulness of T2-weighted fluid-attenuated inversion recovery MR imaging of the CNS. AJR Am. J. Roentgenol. 172, 529-536. doi: 10.2214/ajr.172.2.9930818
2. Albert, M. S., Dekosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., et al. (2011). The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7, 270-279. doi: 10.1016/j.jalz.2011.03.008
3. Alzheimer, A. (1907). u¨ber eine eigenartige Erkrankung der Hirnrinde. Allgemeine Zeitschrift fu¨r Psychiatrie und Psychiatrisch-Gerichtliche Medizin 64, 146-148.
4. Bateman, R. J., Xiong, C., Benzinger, T. L., Fagan, A. M., Goate, A., Fox, N. C., et al. (2012). Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N. Engl. J. Med. 367, 795-804. doi: 10.1056/NEJMoa1202753
5. Bonett, D. G., and Wright, T. A. (2000). Sample size requirements for estimating Pearson, Kendall and Spearman correlations Psychometrika 65, 23-28. doi: 10.1007/BF02294183
6. Braak, H., and Braak, E. (1991). Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82, 239-259. doi: 10.1007/BF00308809
7. Braak, H., and Del Tredici, K. (2012). Where, when, and in what form does sporadic Alzheimer's disease begin? Curr. Opin. Neurol. 25, 708-714. doi: 10.1097/WCO.0b013e32835a3432
8. Brothers, H. M., Bardou, I., Hopp, S. C., Marchalant, Y., Kaercher, R. M., Turner, S. M., et al. (2013). Time-dependent compensatory responses to chronic neuroinflammation in hippocampus and brainstem: the potential role of glutamate neurotransmission. J. Alzheimers. Dis. Parkinsonism 3:110. doi: 10.4172/2161-0460.1000110
9. Carlson, C., Estergard, W., Oh, J., Suhy, J., Jack, C. R. Jr. Siemers, E., et al. (2011). Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer's disease study cohorts from phase 3 trials of semagacestat and solanezumab. Alzheimers. Dement. 7, 396-401. doi: 10.1016/j.jalz.2011.05.2353
10. Cheng, B., Brinkmann, M., Forkert, N. D., Treszl, A., Ebinger, M., Kohrmann, M., et al. (2013). Quantitative measurements of relative fluid-attenuated inversion recovery (FLAIR) signal intensities in acute stroke for the prediction of time from symptom onset. J. Cereb. Blood Flow Metab. 33, 76-84. doi: 10.1038/jcbfm.2012.129
11. Cheng, H. L., Stikov, N., Ghugre, N. R., and Wright, G. A. (2012). Practical medical applications of quantitative MR relaxometry. J. Magn. Reson. Imaging 36, 805-824. doi: 10.1002/jmri.23718
12. Chetelat, G., Villemagne, V. L., Villain, N., Jones, G., Ellis, K. A., Ames, D., et al. (2012). Accelerated cortical atrophy in cognitively normal elderly with high beta-amyloid deposition. Neurology 78, 477-484. doi: 10.1212/WNL.0b013e318246d67a
13. De Coene, B., Hajnal, J. V., Gatehouse, P., Longmore, D. B., White, S. J., Oatridge, A., et al. (1992). MR of the brain using fluid-attenuated inversion recovery (FLAIR) pulse sequences. AJNR Am. J. Neuroradiol. 13, 1555-1564.
14. de Leon, M. J., George, A. E., Stylopoulos, L. A., Smith, G., and Miller, D. C. (1989). Early marker for Alzheimer's disease: the atrophic hippocampus. Lancet 2, 672-673. doi: 10.1016/S0140-6736(89)90911-2
15. Deoni, S. C. (2010). Quantitative relaxometry of the brain. Top. Magn. Reson. Imaging 21, 101-113. doi: 10.1097/RMR.0b013e31821e56d8
16. Fischl, B., Salat, D. H., Van Der Kouwe, A. J., Makris, N., Segonne, F., Quinn, B. T., et al. (2004). Sequence-independent segmentation of magnetic resonance images. Neuroimage 23(Suppl. 1), S69-S84. doi: 10.1016/j.neuroimage.2004.07.016
17. Folstein, M. F., Folstein, S. E., and McHugh, P. R. (1975). "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12, 189-198. doi: 10.1016/0022-3956(75)90026-6
18. Frisoni, G. B. (2012). ARIA from off-key operas? Lancet Neurol. 11, 207-208. doi: 10.1016/S1474-4422(12)70021-2
19. Frisoni, G. B., Winblad, B., and O'Brien, J. T. (2011). Revised NIA-AA criteria for the diagnosis of Alzheimer's disease: a step forward but not yet ready for widespread clinical use. Int. Psychogeriatr. 23, 1191-1196. doi: 10.1017/S1041610211001220
20. Grimmer, T., Faust, M., Auer, F., Alexopoulos, P., Forstl, H., Henriksen, G., et al. (2012). White matter hyperintensities predict amyloid increase in Alzheimer's disease. Neurobiol. Aging 33, 2766-2773. doi: 10.1016/j.neurobiolaging.2012.01.016
21. Ha¨rting, C., Markowitsch, H. J., Neufeld, H., Calabrese, P., Diesinger, K., and Kessler, J. (2000). Wechsler Geda¨chtnis Test - Revidierte Fassung (WMS-R). Bern: Huber.
22. Helmstaedter, C. (2001). Verbaler Lern- und Merkfa¨higkeitstest: VLMT, Manual. Gottingen: Beltz Test GmbH.
23. Helmstaedter, C., and Durwen, H. F. (1990). VLMT: Verbaler Lern- und Merkfa¨higkeitstest [VLMT: Verbal learning and memory test]. Schweizer Archiv fu¨r Neurologie und Psychiatrie 141, 21-30.
24. Hock, C., and Nitsch, R. M. (2000). [Alzheimer dementia]. Praxis 89, 529-540.
25. Holm, S. (1979). A simple sequentially rejective bonferroni test procedure. Scand. J. Stat. 6, 65-70.
26. Howard, A. R. (1950). Diagnostic value of the Wechsler Memory Scale with selected groups of institutionalized patients. J. Consult. Psychol. 14, 376-380. doi: 10.1037/h0058479
27. Iacono, D., O'Brien, R., Resnick, S. M., Zonderman, A. B., Pletnikova, O., Rudow, G., et al. (2008). Neuronal hypertrophy in asymptomatic Alzheimer disease. J. Neuropathol. Exp. Neurol. 67, 578-589. doi: 10.1097/NEN.0b013e3181772794
28. Iseki, E., Matsushita, M., Kosaka, K., Kondo, H., Ishii, T., and Amano, N. (1989). Distribution and morphology of brain stem plaques in Alzheimer's disease. Acta Neuropathol. 78, 131-136. doi: 10.1007/BF00688200
29. Jack, C. R. Jr., and Holtzman, D. M. (2013). Biomarker modeling of Alzheimer's disease. Neuron 80, 1347-1358. doi: 10.1016/j.neuron.2013.12.003
30. Jack, C. R. Jr. Lowe, V. J., Weigand, S. D., Wiste, H. J., Senjem, M. L., Knopman, D. S., et al. (2009). Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 132, 1355-1365. doi: 10.1093/brain/awp062
31. Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., et al. (2004). Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann. Neurol. 55, 306-319. doi: 10.1002/ana.20009
32. Knopman, D. S., Parisi, J. E., Salviati, A., Floriach-Robert, M., Boeve, B. F., Ivnik, R. J., et al. (2003). Neuropathology of cognitively normal elderly. J. Neuropathol. Exp. Neurol. 62, 1087-1095.
33. Lezak, M. D. (1983). Neuropsychological Assessment, 2nd Edn. New York, NY: Oxford University Press.
34. Lowe, V. J., Weigand, S. D., Senjem, M. L., Vemuri, P., Jordan, L., Kantarci, K., et al. (2014). Association of hypometabolism and amyloid levels in aging, normal subjects. Neurology 82, 1959-1967. doi: 10.1212/WNL.0000000000000467
35. Mackay, N. J. (2010). Scaling of human body mass with height: the body mass index revisited. J. Biomech. 43, 764-766. doi: 10.1016/j.jbiomech.2009.10.038
36. Maetzler, W., Reimold, M., Liepelt, I., Solbach, C., Leyhe, T., Schweitzer, K., et al. (2008). [11C]PIB binding in Parkinson's disease dementia. Neuroimage 39, 1027-1033. doi: 10.1016/j.neuroimage.2007.09.072
37. Mathis, C. A., Wang, Y., Holt, D. P., Huang, G. F., Debnath, M. L., and Klunk, W. E. (2003). Synthesis and evaluation of 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J. Med. Chem. 46, 2740-2754. doi: 10.1021/jm030026b
38. Mintun, M. A., Larossa, G. N., Sheline, Y. I., Dence, C. S., Lee, S. Y., Mach, R. H., et al. (2006). [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 67, 446-452. doi: 10.1212/01.wnl.0000228230.26044.a4
39. Mormino, E. C., Brandel, M. G., Madison, C. M., Rabinovici, G. D., Marks, S., Baker, S. L., et al. (2012). Not quite PIB-positive, not quite PIB-negative: slight PIB elevations in elderly normal control subjects are biologically relevant. Neuroimage 59, 1152-1160. doi: 10.1016/j.neuroimage.2011.07.098
40. Mormino, E. C., Kluth, J. T., Madison, C. M., Rabinovici, G. D., Baker, S. L., Miller, B. L., et al. (2009). Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain 132, 1310-1323. doi: 10.1093/brain/awn320
41. Mu¨ller, H., Hasse-Sander, I., Horn, R., Helmstaedter, C., and Elger, C. E. (1997). Rey Auditory-Verbal Learning Test: structure of a modified German version. J. Clin. Psychol. 53, 663-671.
42. Neema, M., Guss, Z. D., Stankiewicz, J. M., Arora, A., Healy, B. C., and Bakshi, R. (2009). Normal findings on brain fluid-attenuated inversion recovery MR images at 3T. AJNR Am. J. Neuroradiol. 30, 911-916. doi: 10.3174/ajnr. A1514
43. Nicholas, L. E., Brookshire, R. H., MacLennan, D. L., Schumacher, J. G., and Porrazzo, S. A. (1988). The boston naming test: revised administration and scoring procedures and normative information for non-brain-damaged adults. Clin. Aphasiol. 18, 103-115.
44. Parvizi, J., Van Hoesen, G. W., and Damasio, A. (2001). The selective vulnerability of brainstem nuclei to Alzheimer's disease. Ann. Neurol. 49, 53-66. doi: 10.1002/1531-8249(200101)49:1%3C53::AID-ANA30%3E3.0.CO;2-Q
45. Pell, G. S., Briellmann, R. S., Waites, A. B., Abbott, D. F., and Jackson, G. D. (2004). Voxel-based relaxometry: a new approach for analysis of T2 relaxometry changes in epilepsy. Neuroimage 21, 707-713. doi: 10.1016/j.neuroimage.2003.09.059
46. Petersen, R. C., Smith, G. E., Waring, S. C., Ivnik, R. J., Tangalos, E. G., and Kokmen, E. (1999). Mild cognitive impairment: clinical characterization and outcome. Arch. Neurol. 56, 303-308. doi: 10.1001/archneur.56.3.303
47. Price, J. C., Klunk, W. E., Lopresti, B. J., Lu, X., Hoge, J. A., Ziolko, S. K., et al. (2005). Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J. Cereb. Blood Flow Metab. 25, 1528-1547. doi: 10.1038/sj.jcbfm.9600146
48. Price, J. L., and Morris, J. C. (1999). Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann. Neurol. 45, 358-368.
49. Reitan, R. M. (1958). Validity of the Trail Making Test as an indicator of organic brain damage. Percept. Mot. Skills 8, 271-276. doi: 10.2466/pms.1958.8.3.271
50. Riudavets, M. A., Iacono, D., Resnick, S. M., O'Brien, R., Zonderman, A. B., Martin, L. J., et al. (2007). Resistance to Alzheimer's pathology is associated with nuclear hypertrophy in neurons. Neurobiol. Aging 28, 1484-1492. doi: 10.1016/j.neurobiolaging.2007.05.005
51. Rodrigue, K. M., Kennedy, K. M., Devous, M. D. Sr. Rieck, J. R., Hebrank, A. C., Diaz-Arrastia, R., et al. (2012). beta-Amyloid burden in healthy aging: regional distribution and cognitive consequences. Neurology 78, 387-395. doi: 10.1212/WNL.0b013e318245d295
52. Savva, G. M., Wharton, S. B., Ince, P. G., Forster, G., Matthews, F. E., Brayne, C., et al. (2009). Age, neuropathology, and dementia. N. Engl. J. Med. 360, 2302-2309. doi: 10.1056/NEJMoa0806142
53. Serrano-Pozo, A., Frosch, M. P., Masliah, E., and Hyman, B. T. (2011). Neuropathological alterations in Alzheimer disease. Cold Spring Harb. Perspect. Med. 1:a006189. doi: 10.1101/cshperspect.a006189
54. Sheline, Y. I., Raichle, M. E., Snyder, A. Z., Morris, J. C., Head, D., Wang, S., et al. (2010). Amyloid plaques disrupt resting state default mode network connectivity in cognitively normal elderly. Biol. Psychiatry 67, 584-587. doi: 10.1016/j.biopsych.2009.08.024
55. Simic, G., Stanic, G., Mladinov, M., Jovanov-Milosevic, N., Kostovic, I., and Hof, P. R. (2009). Does Alzheimer's disease begin in the brainstem? Neuropathol. Appl. Neurobiol. 35, 532-554. doi: 10.1111/j.1365-2990.2009.01038.x
56. Solbach, C., Uebele, M., Reischl, G., and Machulla, H. J. (2005). Efficient radiosynthesis of carbon-11 labelled uncharged Thioflavin T derivatives using [11C]methyl triflate for beta-amyloid imaging in Alzheimer's disease with PET. Appl. Radiat. Isot. 62, 591-595. doi: 10.1016/j.apradiso.2004.09.003
57. Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., et al. (2011). Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7, 280-292. doi: 10.1016/j.jalz.2011.03.003
58. Sperling, R. A., Johnson, K. A., Doraiswamy, P. M., Reiman, E. M., Fleisher, A. S., Sabbagh, M. N., et al. (2013). Amyloid deposition detected with florbetapir F 18 ((18)F-AV-45) is related to lower episodic memory performance in clinically normal older individuals. Neurobiol. Aging 34, 822-831. doi: 10.1016/j.neurobiolaging.2012.06.014
59. Sperling, R., Salloway, S., Brooks, D. J., Tampieri, D., Barakos, J., Fox, N. C., et al. (2012). Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol. 11, 241-249. doi: 10.1016/S1474-4422(12)70015-7
60. Steffener, J., and Stern, Y. (2012). Exploring the neural basis of cognitive reserve in aging. Biochim. Biophys. Acta 1822, 467-473. doi: 10.1016/j.bbadis.2011.09.012
61. Steininger, S. C., Liu, X., Gietl, A., Wyss, M., Schreiner, S., Gruber, E., et al. (2014). Cortical amyloid beta in cognitively normal elderly adults is associated with decreased network efficiency within the cerebro-cerebellar system. Front. Aging Neurosci. 6:52. doi: 10.3389/fnagi.2014.00052
62. Su, Y., D'angelo, G. M., Vlassenko, A. G., Zhou, G., Snyder, A. Z., Marcus, D. S., et al. (2013). Quantitative analysis of PiB-PET with FreeSurfer ROIs. PLoS ONE 8:e73377. doi: 10.1371/journal.pone.0073377
63. Thalmann, B., Monsch, A. U., Bernasconi, F., Berres, M., Schneitter, M., Ermini-Fu¨nfschilling, D., et al. (1997). CERAD - Consortium to Establish a Registry for Alzheimer's Disease Assessment Battery - Deutsche Fassung. Basel: Geriatrische Universita¨tsklinik.
64. Tombaugh, T. N. (2004). Trail Making Test A and B: normative data stratified by age and education. Arch. Clin. Neuropsychol. 19, 203-214. doi: 10.1016/S0887-6177(03)00039-8
65. Unschuld, P. G., Edden, R. A., Carass, A., Liu, X., Shanahan, M., Wang, X., et al. (2012a). Brain metabolite alterations and cognitive dysfunction in early Huntington's disease. Mov. Disord. 27, 895-902. doi: 10.1002/mds.25010
66. Unschuld, P. G., Joel, S. E., Liu, X., Shanahan, M., Margolis, R. L., Biglan, K. M., et al. (2012b). Impaired cortico-striatal functional connectivity in prodromal Huntington's Disease. Neurosci. Lett. 514, 204-209. doi: 10.1016/j.neulet.2012.02.095
67. Unschuld, P. G., Liu, X., Shanahan, M., Margolis, R. L., Bassett, S. S., Brandt, J., et al. (2013). Prefrontal executive function associated coupling relates to Huntington's disease stage. Cortex 49, 2661-2673. doi: 10.1016/j.cortex.2013.05.015
68. Vandenberghe, R., Van Laere, K., Ivanoiu, A., Salmon, E., Bastin, C., Triau, E., et al. (2010). 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann. Neurol. 68, 319-329. doi: 10.1002/ana.22068
69. Visser, F., Zwanenburg, J. J., Hoogduin, J. M., and Luijten, P. R. (2010). High-resolution magnetization-prepared 3D-FLAIR imaging at 7.0 Tesla. Magn. Reson. Med. 64, 194-202. doi: 10.1002/mrm.22397
70. Winblad, B., Palmer, K., Kivipelto, M., Jelic, V., Fratiglioni, L., Wahlund, L. O., et al. (2004). Mild cognitive impairment-beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J. Intern. Med. 256, 240-246. doi: 10.1111/j.1365-2796.2004.01380.x
71. World_Medical_Association. (1991). Declaration of Helsinki. Law Med. Health Care 19, 264-265.
72. Young, V. G., Halliday, G. M., and Kril, J. J. (2008). Neuropathologic correlates of white matter hyperintensities. Neurology 71, 804-811. doi: 10.1212/01.wnl.0000319691.50117.54
73. Zwanenburg, J. J., Hendrikse, J., Visser, F., Takahara, T., and Luijten, P. R. (2010). Fluid attenuated inversion recovery (FLAIR) MRI at 7.0 Tesla: comparison with 1.5 and 3.0 Tesla. Eur. Radiol. 20, 915-922. doi: 10.1007/s00330-009-1620-2